Caricamento...
Tolerability of Omalizumab in Asthma as a Major Compliance Factor: 10-Year Follow Up
BACKGROUND: There is a lack of data related to real life, long-term safety, tolerability and compliance of omalizumab treatment in asthma patients beyond 6 years. AIM: Study aimed to assess safety, tolerability, compliance and all reasons for treatment discontinuation during 10 years on omalizumab....
Salvato in:
| Pubblicato in: | Open Access Maced J Med Sci |
|---|---|
| Autori principali: | , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Republic of Macedonia
2018
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6236047/ https://ncbi.nlm.nih.gov/pubmed/30455759 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3889/oamjms.2018.394 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|